Press Release
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.
The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.
More information about Desidustat Tablets and Renal Anaemia
As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.
There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.
Desidustat Tablets have been approved for marketing in India.
CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.
The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference
1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6
2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015
3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)
4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Maui, HI, 29th April 2026, ZEX PR WIRE — A West Maui & Molokai helicopter tour is one of the most awe-inspiring aerial experiences in Hawaii, offering a front-row seat to landscapes that are simply unreachable by land. From the moment you lift off, you’re immersed in a world of towering sea cliffs, hidden valleys, cascading waterfalls, and lush rainforests that stretch as far as the eye can see.
The journey begins over West Maui, where dramatic ridgelines and emerald-green mountains rise sharply from the coastline. As the helicopter glides through the valleys, you’ll witness waterfalls pouring down sheer rock faces—some appearing only after rainfall, making every flight a unique experience. The untouched beauty of this region feels almost prehistoric, giving you a sense of stepping into a lost world.
As the tour continues toward Molokai, the scenery becomes even more breathtaking. Molokai is home to some of the tallest sea cliffs in the world, soaring nearly 4,000 feet above the Pacific Ocean. From above, you’ll see massive waterfalls plunging directly into the ocean and deep valleys carved over millions of years. The isolation and raw beauty of Molokai create a powerful contrast to the more developed Hawaiian islands, making this portion of the flight truly unforgettable.
Throughout the tour, expert pilots provide guided narration, sharing insights about the history, geology, and cultural significance of the islands. With panoramic windows and smooth flight paths, every passenger gets a perfect view—ideal for capturing once-in-a-lifetime photos and videos.
Exclusive Offers & Packages
BOOK TODAY & YOU’LL RECEIVE 7% OFF ALL FUTURE FLIGHTS OVER HAWAII!
Helicopter flight packages are available starting at $1000, delivering a premium experience designed for both adventure and luxury seekers.
What’s Included?
- FREE DINNER
- FREE B-DAY VACATION
- 10% OFF PARTY BUS / RIDE SERVICE
- COMPLIMENTARY CHAMPAGNE
Whether you’re celebrating a special occasion, planning a romantic getaway, or simply looking to elevate your travel experience, a West Maui & Molokai helicopter tour delivers unmatched beauty, exclusivity, and unforgettable memories from the sky.
Contact
Business Name: Hawaii’s Private Helicopter Tour Service
Contact Name: Dujaun Hayles
Contact Number: 808-862-2279
Email: Dujaunhayles@gmail.com
Website: https://privatehelicoptertoursinhawaii.weebly.com/molokai-helicopter-tours.html
Tiktok: https://www.tiktok.com/@privatehelicoptertours/video/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
IPO Genie Nears 1.5M Dollars Raised as Demand Accelerates for Tokenized Pre-IPO Opportunities
United States, 29th Apr 2026 – IPO Genie, an emerging blockchain-based investment platform, is approaching the $1.5 million mark in its ongoing crypto presale, reflecting growing interest in tokenized access to private markets. The milestone highlights a broader shift in investor behavior as digital assets increasingly intersect with traditional finance, particularly in the area of pre-IPO opportunities.
The platform is designed to provide structured access to private-market deals that have historically been limited to institutional investors and high-net-worth individuals. By integrating blockchain infrastructure with AI-driven analysis, IPO Genie aims to streamline how users discover, evaluate, and participate in early-stage investment opportunities.
The rise in participation comes at a time when crypto presale models are evolving beyond speculative tokens toward utility-focused ecosystems. In this context, tokenized pre-IPO opportunities represent a growing category, offering exposure to companies before public listings through digital frameworks that emphasize transparency and accessibility.
IPO Genie’s approach centers on aggregating private-market data and presenting it through a structured workflow, including risk indicators, eligibility requirements, and deal-specific insights. This model reflects a broader trend toward data-driven investment tools within Web3, where automation and analytics play a larger role in decision-making.
At the same time, the increasing interest in pre-IPO opportunities within the crypto presale landscape underscores a shift toward earlier-stage participation. Investors are seeking exposure to potential growth phases that occur prior to traditional market entry, supported by platforms that reduce barriers to access.
While the sector continues to develop, the convergence of blockchain technology, artificial intelligence, and private equity access signals an ongoing transformation in how early-stage investments are approached. IPO Genie’s fundraising progress reflects this evolving demand, as tokenized models continue to reshape participation in private markets.
Media Contact
Organization: IPO Genie
Contact Person: Mark
Website: https://ipogenie.ai/
Email: Send Email
Country:United States
Release id:44531
Disclaimer: This press release is for informational purposes only and does not constitute investment, financial, legal, or regulatory advice. Readers should conduct independent research and consult qualified professionals before making any decisions.
The post IPO Genie Nears 1.5M Dollars Raised as Demand Accelerates for Tokenized Pre-IPO Opportunities appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Kuwait, 29th Apr 2026 – Ubuy, a leading global cross-border e-commerce platform, has been honoured with the prestigious “Cross-Border Brand of the Year” at the IReC X D2C Awards 2026 ceremony held at the Sheraton Grand Hotel, Bangalore.
The award recognises Ubuy’s consistent growth and its role in making international shopping more accessible for consumers across more than 180 countries. By reducing the barriers traditionally associated with cross-border commerce, Ubuy has enabled customers to shop globally with greater confidence and convenience.
Unlike traditional e-commerce models that are limited by geography or inventory, Ubuy operates on a cross-border commerce infrastructure that connects customers with a vast catalogue of international products. Its platform is powered by globally compliant systems that meet international standards for data handling, transactions, and operations, combined with intelligent sourcing and a robust logistics network supported by multiple global warehouses, enabling customers to shop from international markets with reliability and confidence.
“We are honoured to receive this recognition at IReC X D2C Awards 2026,” said Mr Dinesh, Director at Ubuy. “For us, this is not just about growth, it is about consistently delivering value to our customers by making international shopping more accessible, transparent, and reliable.”
To further strengthen the overall shopping experience, Ubuy continues to optimise key aspects of the customer journey. With faster international shipping enabled by its global logistics network, region-specific payment options, and a simplified return process, the platform removes common friction points associated with cross-border purchases. Its mobile applications extend this capability, allowing customers to seamlessly browse, track, and manage orders. This is supported by dedicated 24×7 customer assistance, ensuring a consistent and reliable experience across markets.
What sets Ubuy apart is its ability to give customers access to products that are often unavailable in their local markets, while handling the complexities of international shopping on their behalf. From sourcing products from global marketplaces to managing shipping, customs, and delivery, Ubuy simplifies the entire cross-border journey into a single, reliable experience.
About Ubuy:
Ubuy is the leading cross-border e-commerce platform trusted by millions of consumers worldwide. The company’s mission is to provide a seamless, authentic, and trusted shopping experience to its consumers.
Media Contact
Organization: Ubuy
Contact Person: Faizan Khan
Website: https://ubuy.com/
Email: Send Email
Contact Number: +96522204472/ 22055305
Address:Al Murqab, Block 3, Khalid Ibn Al Waleed Street,
Address 2: Mazaya Tower 3, Floor 22
State: Kuwait
Country:Kuwait
Release id:44497
The post Ubuy Wins Cross-Border Brand of the Year at IReC X D2C Awards 2026 appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Hawaii Helicopter Tours | West Maui & Molokai Helicopter Tour Experience
IPO Genie Nears 1.5M Dollars Raised as Demand Accelerates for Tokenized Pre-IPO Opportunities
Ubuy Wins Cross-Border Brand of the Year at IReC X D2C Awards 2026
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release5 days ago
Indian Entrepreneur G. Satya Sai Gains National Attention as Founder Driving AI, Cybersecurity and Startup Innovation in 2026
-
Press Release5 days ago
Floors To Your Home Encourages Buyers to Ask One Key Question Before Purchasing Flooring Online
-
Press Release5 days ago
Dr B Palvan Recognized for Public Health Leadership and Excellence in Dermatology
-
Press Release7 days ago
Coast to Coast Hole in One Helps Golf Events Nationwide Offer High-Value Prizes Through Trusted Hole in One Insurance
-
Press Release4 days ago
AntNest $1,000,000 Genesis Airdrop is LIVE! Play games to Win Big！
-
Press Release5 days ago
Is This Secret AI Engine Draining Polymarket: On-Chain Data Reveals a New Whale in Prediction Markets
-
Press Release1 week ago
How Platforms Like XONE Fit Into the Convergence of Policy, Real Assets, and AI in Digital Finance
-
Press Release2 days ago
TianYi High-Tech Launches TA Series Carbide Roller Rings for High-Speed Rolling Mills